Aldeyra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Aldeyra Therapeutics has a total shareholder equity of $113.4M and total debt of $15.2M, which brings its debt-to-equity ratio to 13.4%. Its total assets and total liabilities are $141.3M and $27.9M respectively.
Key information
13.4%
Debt to equity ratio
US$15.20m
Debt
| Interest coverage ratio | n/a |
| Cash | US$83.04m |
| Equity | US$113.42m |
| Total liabilities | US$27.88m |
| Total assets | US$141.30m |
Recent financial health updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Aldeyra initiates stock offering
Jan 13Aldeyra rated buy at Citi on reproxalap trial results
Jan 08Aldeyra's reproxalap improves dry eye disease symptoms, run-in cohort shows
Jan 07How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Do Institutions Own?
Jan 01
Financial Position Analysis
Short Term Liabilities: ALDX's short term assets ($140.8M) exceed its short term liabilities ($21.7M).
Long Term Liabilities: ALDX's short term assets ($140.8M) exceed its long term liabilities ($6.2M).
Debt to Equity History and Analysis
Debt Level: ALDX has more cash than its total debt.
Reducing Debt: ALDX's debt to equity ratio has increased from 0% to 13.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALDX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 6.3% each year.